Does Anthem Cover Dupixent?

What Is Dupixent and Why Does Coverage Get Complicated?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, two cytokines central to Type 2 inflammatory disease. The FDA has approved it for six distinct indications since 2017, and each approval carries its own set of clinical criteria that insurers, including Anthem, translate into prior authorization (PA) checklists.

The FDA-Approved Indications That Anthem Evaluates

The FDA first approved dupilumab in March 2017 for adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical therapies. Subsequent approvals expanded the label to include [1]:

• Atopic dermatitis: adults and children aged 6 months and older with moderate-to-severe disease
• Asthma: adults and children aged 6 years and older with moderate-to-severe eosinophilic phenotype, or oral-steroid-dependent asthma
• Chronic rhinosinusitis with nasal polyps (CRSwNP): adults aged 18 and older
• Eosinophilic esophagitis (EoE): adults and children aged 12 years and older weighing at least 40 kg
• Prurigo nodularis: adults aged 18 and older
• Chronic spontaneous urticaria (CSU): adults and adolescents 12 and older inadequately controlled on antihistamines

Anthem's clinical criteria documents are keyed to these approvals. An off-label request will almost certainly be denied at the initial review level regardless of medical rationale. [2]

Why Anthem Places Dupixent on a High Specialty Tier

Specialty biologics routinely land on Tier 4 or Tier 5 because their wholesale acquisition cost is substantially higher than small-molecule drugs. Dupixent's list price sits at roughly $3,000-$3,250 per 300 mg syringe, which translates to approximately $36,000-$39,000 annually for the standard atopic dermatitis maintenance regimen (300 mg every two weeks). [3] Anthem's pharmacy benefit managers negotiate rebates that lower the plan's net cost, but patient cost-sharing is calculated against the list price on many plan designs, making the copay card programs described below practically essential.

How Anthem's Prior Authorization Process Works for Dupixent

Prior authorization is mandatory across essentially all Anthem commercial, Medicaid managed care, and Medicare Advantage plans. The process has three phases: clinical documentation submission, medical review, and (if approved) ongoing re-authorization at 6-to-12-month intervals.

Phase 1: Clinical Documentation Anthem Typically Requires

The PA packet your dermatologist, allergist, or gastroenterologist submits should generally include [4]:

• A diagnosis code matching an FDA-approved indication (e.g., L20.9 for atopic dermatitis, J45.50 for moderate persistent asthma)
• Documented disease severity scores. For atopic dermatitis, the Eczema Area and Severity Index (EASI) or Investigator Global Assessment (IGA) score is standard. EASI scores of 16 or higher (moderate-to-severe range) typically satisfy Anthem's threshold.
• Evidence of step-therapy failure with at least one, and sometimes two, prior conventional agents. For atopic dermatitis this usually means topical corticosteroids (TCS) of medium-to-high potency and at least one topical calcineurin inhibitor (TCI) such as tacrolimus or pimecrolimus.
• Documentation of any contraindications to the required step-therapy agents (e.g., skin atrophy, cataracts, or facial involvement where prolonged TCS use is contraindicated).
• Recent laboratory or clinical records supporting the severity assessment.

The American Academy of Dermatology guidelines define moderate-to-severe atopic dermatitis as an IGA score of 3 or 4 and an affected body surface area greater than 10%, criteria that Anthem's clinical reviewers reference directly. [5]

Phase 2: Medical Review Timeline

After complete submission, Anthem's standard commercial turnaround is 14 calendar days for non-urgent cases. Urgent or expedited reviews, which apply when a standard timeframe could seriously jeopardize health, must be completed within 72 hours under federal Affordable Care Act regulations. [6] Physicians should request expedited review in writing with a clinical justification when a patient is experiencing acute flares or significant quality-of-life impairment.

Phase 3: Re-Authorization Cadence

Anthem typically grants initial approval for 6-12 months. Re-authorization requires updated clinical notes showing the patient's response, which for atopic dermatitis means at least a 50% reduction in EASI score or documented improvement in patient-reported outcomes. The SOLO 1 and SOLO 2 trials (combined N=1,379) showed dupilumab 300 mg every two weeks produced an IGA 0 or 1 response in 37-38% of patients versus 10% for placebo at 16 weeks, [7] data your physician can cite directly in the re-auth letter to demonstrate expected benefit.

Step Therapy Requirements by Indication

Step therapy, sometimes called "fail-first," is the most common reason Dupixent PAs are delayed or denied outright. Anthem's requirements differ by indication.

Atopic Dermatitis Step Therapy

For adults and children with atopic dermatitis, Anthem typically requires a documented trial of:

1. A medium-to-high-potency topical corticosteroid for at least 4-8 weeks
2. A topical calcineurin inhibitor (tacrolimus 0.1% ointment or pimecrolimus cream) for at least 4-8 weeks, or documented contraindication

Some Anthem plans also require a trial of crisaborole (Eucrisa) ointment, a PDE4 inhibitor, before approving dupilumab. Whether that third step applies depends on the specific plan document, so always pull the actual formulary or call Anthem's pharmacy line (the number is on the back of the member ID card).

Asthma Step Therapy

For moderate-to-severe eosinophilic asthma, Anthem generally requires:

• Current use of an inhaled corticosteroid (ICS) at medium-to-high dose plus a long-acting beta-agonist (LABA)
• An absolute eosinophil count of at least 150-300 cells per microliter, or documented oral corticosteroid dependence

The QUEST trial (N=1,902) demonstrated dupilumab 200 mg or 300 mg every two weeks reduced annualized severe exacerbation rates by 47.7% versus placebo and improved FEV1 by 0.32 L at 52 weeks in patients with baseline eosinophils at or above 300 cells per microliter. [8] Submitting that trial data alongside the patient's eosinophil count strengthens the PA substantially.

CRSwNP, EoE, Prurigo Nodularis, and CSU

For chronic rhinosinusitis with nasal polyps, Anthem usually requires a nasal polyp score of 5 or greater (bilateral), prior intranasal corticosteroid use, and in some plans, a prior course of systemic corticosteroids.

For eosinophilic esophagitis, Anthem generally requires a prior documented 8-week trial of a proton pump inhibitor and histopathologic confirmation of at least 15 eosinophils per high-power field on esophageal biopsy. [9]

Prurigo nodularis and CSU approvals are newer, following the 2022 and 2024 FDA approvals respectively, so Anthem's clinical criteria for those indications are still being updated. Confirm the current criteria with Anthem's medical policy unit before submitting.

What Happens After a Denial

Anthem denials are not final. Federal law and most state insurance regulations give patients and providers a structured appeals process with specific timelines.

Internal Appeal

The first step is an internal (first-level) appeal filed directly with Anthem, typically within 180 days of the denial notice. The appeal should include [6]:

• A physician-authored letter citing specific trial data (SOLO 1/2, QUEST, LIBERTY-NP SINUS-24) and explaining why step-therapy alternatives were inadequate or contraindicated
• Updated severity scores (EASI, IGA, ACQ, nasal polyp score as applicable)
• Published guidelines from the American Academy of Allergy, Asthma and Immunology or the American Academy of Dermatology supporting dupilumab as a first-line biologic after conventional failure [5]
• Letters of medical necessity from the treating specialist

Anthem must respond to a standard internal appeal within 30 days for prospective requests and 60 days for retrospective requests.

External Independent Review

If the internal appeal fails, patients on fully-insured commercial plans have the right to an external independent review organization (IRO) review under ACA Section 2719. [6] The IRO's decision is binding on Anthem. Studies of external reviews across multiple insurers show overturn rates of 30-50% for biologic PA denials when the clinical record is well-documented.

State-Level Protections and Step Therapy Override Laws

Over 30 states have enacted step-therapy reform laws that give physicians explicit authority to request a step-therapy exception when [10]:

• The required drug is contraindicated or likely to cause an adverse reaction
• The patient previously failed the required drug on the same or a different plan
• The required drug would be ineffective based on clinical evidence

If your state has a step-therapy override law, cite it in the appeal. The National Alliance of Mental Illness (NAMI) and the Psoriasis Foundation maintain updated state-by-state maps.

Reducing Out-of-Pocket Cost: The Dupixent MyWay Program

Even with Anthem approval, specialty tier cost-sharing can run into hundreds or thousands of dollars per month. Sanofi and Regeneron operate the Dupixent MyWay copay assistance program for commercially insured patients who are not enrolled in a government-funded plan. [11]

How the Copay Card Works

Eligible patients with commercial insurance (Anthem commercial, not Anthem Medicaid or Medicare Advantage) can pay as little as $0 per month for their Dupixent prescription through the MyWay card. The program covers the gap between Anthem's allowed amount and the patient's share up to a defined annual maximum, which has historically been $13,000-$26,000 per year. Enrollment takes roughly 10 minutes at dupixent.com or by calling 1-844-DUPIXENT.

Patients Without Commercial Insurance

Patients on Anthem Medicaid managed care or Anthem Medicare Advantage cannot use the manufacturer copay card due to federal anti-kickback statute restrictions. Instead, the Dupixent MyWay program can refer these patients to independent charitable foundations, including the Healthwell Foundation and the Patient Advocate Foundation, which offer separate grant programs. [12]

Specialty Pharmacy Routing

Anthem routes most Dupixent prescriptions through its preferred specialty pharmacy network. Curascript SD, AllianceRx Walgreens, and CVS Specialty are common Anthem-preferred options. Using a non-preferred specialty pharmacy can result in a higher cost-sharing tier or denial of the specialty benefit, so always confirm the dispensing pharmacy with Anthem before the first fill.

Clinical Evidence Supporting Dupixent Across Indications

Anthem's clinical policy documents are grounded in the same trial data that drove FDA approval decisions. Understanding that data helps providers write stronger PA letters.

Atopic Dermatitis: The SOLO and LIBERTY AD Trials

The SOLO 1 and SOLO 2 trials (combined N=1,379) showed dupilumab 300 mg every two weeks achieved IGA 0 or 1 in 37-38% of patients at 16 weeks versus 8-10% for placebo (P<0.001). [7] The LIBERTY AD CHRONOS trial (N=740) extended follow-up to 52 weeks and demonstrated sustained efficacy with concomitant low-potency topical corticosteroids, with 39% of dupilumab patients achieving IGA 0 or 1 versus 12% for placebo plus TCS at week 52. [13]

Asthma: QUEST Trial at 52 Weeks

In QUEST (N=1,902), dupilumab reduced annualized exacerbation rates by 47.7% in the overall population and by 65.8% in patients with baseline eosinophils at or above 300 cells per microliter. Mean improvement in pre-bronchodilator FEV1 was 0.32 L at week 52 for the 300 mg every-two-weeks dose in the high-eosinophil subgroup (P<0.001). [8]

CRSwNP: LIBERTY-NP SINUS-24 and SINUS-52

The SINUS-24 (N=276) and SINUS-52 (N=448) trials showed dupilumab 300 mg every two weeks reduced nasal polyp score by 2.06 points (SINUS-24) and 2.05 points (SINUS-52) from baseline versus placebo reductions of 0.28 and 0.17 points respectively (P<0.001). [14]

Eosinophilic Esophagitis: LIBERTY EoE TREET

The LIBERTY EoE TREET trial (N=240, Part A) showed dupilumab 300 mg every two weeks produced histologic remission (fewer than 6 eosinophils per high-power field) in 59% of patients at 24 weeks versus 6% for placebo (P<0.001). [9] Anthem's EoE clinical criteria map directly to this histologic threshold.

A Practical Submission Checklist for Providers

Using this checklist before submitting to Anthem reduces the rate of incomplete-submission delays, which account for a substantial share of initial processing holds.

Before submitting the PA:

• Confirm the patient's Anthem plan type (commercial, Medicaid managed care, Medicare Advantage) because criteria differ
• Pull the current Anthem clinical policy bulletin (CPB) for dupilumab from anthem.com/provider or call Anthem's provider line
• Obtain and document a severity score (EASI, IGA, ACQ-6, NPS, or endoscopy report as appropriate)
• Record the start and stop dates, doses, and responses for all required step-therapy agents
• Note any contraindications to step-therapy agents in the chart
• Confirm the dispensing specialty pharmacy is in Anthem's preferred network

In the PA letter itself:

• State the FDA-approved indication and corresponding ICD-10 code explicitly
• Quote the relevant trial data: SOLO 1/2 for atopic dermatitis, QUEST for asthma, SINUS-24/52 for CRSwNP, LIBERTY EoE TREET for EoE
• Reference Anthem's own clinical policy document by number if available
• Cite the applicable specialty society guideline (AAD, AAAAI, ACG as appropriate) [5]
• Request expedited review in writing if the patient's condition warrants it

The American Academy of Allergy, Asthma and Immunology's published position statement notes that "dupilumab has demonstrated consistent efficacy across multiple type 2 inflammatory conditions, supporting its use when conventional therapies have failed," [15] a direct quotation providers can include verbatim in appeal letters.

Anthem Medicaid and Medicare Advantage: Different Rules Apply

Anthem Medicaid Managed Care

Anthem administers Medicaid managed care in several states, including California (through Anthem Blue Cross Partnership Plan), Virginia (Anthem HealthKeepers Plus), and others. Medicaid clinical criteria for Dupixent can be more restrictive than commercial criteria or, in some states, more permissive due to state drug utilization review (DUR) board decisions. Step-therapy failure documentation requirements are generally similar, but the specialty pharmacy network and copay structure differ entirely since Medicaid cost-sharing is capped by federal law at nominal amounts.

Anthem Medicare Advantage

Medicare Part D covers Dupixent under the prescription drug benefit. Anthem Medicare Advantage plans place dupilumab on their highest specialty tier. The standard 25% coinsurance on a $36,000/year drug translates to $9,000 out of pocket before the catastrophic coverage threshold kicks in. Starting in 2025, the Inflation Reduction Act caps Medicare Part D out-of-pocket spending at $2,000 per year, [6] which substantially changes the cost math for Medicare Advantage patients who previously faced five-figure annual costs.

The $2,000 annual cap applies to all Anthem Medicare Advantage Part D enrollees beginning January 1, 2025.

Frequently Asked Questions